Sugi Predict

Sugi Predict / Compounds / SCHEMBL10809

SCHEMBL10809

SCHEMBL10809

C=C(C)C(=O)N(CCC)c1c(O)cccc1O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.36
▸ HTR1A P08908 1/20 0.36
▸ CA12 O43570 3/20 0.35
▸ CA1 P00915 3/20 0.35
▸ CA2 P00918 3/20 0.35
▸ CA9 Q16790 3/20 0.35
▸ CA7 P43166 2/20 0.35
▸ CA14 Q9ULX7 2/20 0.35
▸ TP53 P04637 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ ATM Q13315 1/20 0.35
▸ DRD2 P14416 1/20 0.34
▸ IAPP P10997 2/20 0.33
▸ ESR1 P03372 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27976696 0.83 IAPP (0.37) THRBHTR1ACA12CA1CA2
SCHEMBL28353012 0.77 TP53 (0.53) TP53MEN1ALDH1A1HTTKMT2A
SCHEMBL28750176 0.75 ESR1 (0.42) CA12CA1CA2CA9CA7
SCHEMBL28591966 0.75 SERPINE1 (0.41) THRBCA12CA1CA2CA9
Phenol SCHEMBL28090452 0.68 ALOX5 (0.42) CA12CA1CA2CA9CA14
SCHEMBL28177519 0.68 NPC1 (0.54) TP53MEN1ALDH1A1MAPTKMT2A
SCHEMBL286789 0.66 ALDH1A1 (0.63) TP53MEN1ALDH1A1MAPTHTT
SCHEMBL14087159 0.66 NPC1 (0.62) THRBTP53MEN1ALDH1A1MAPT
Pyrogallol SCHEMBL28231306 0.66 ERN1 (0.40) THRBCA12CA1CA2CA9
SCHEMBL253747 0.65 HTR1A (0.36) HTR1ATP53ALDH1A1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226319-A1 EGFR TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES MERCK PATENT GMBH (DE) 2024-07-11 — — US disclosed
WO-2024099898-A1 SUBSTITUTED BI-AND TRICYCLIC HSET INHIBITORS MERCK PATENT GMBH (DE) 2024-05-16 — — WO disclosed
EP-4041274-B1 WS-635 FOR USE IN THE TREATMENT OF POSTOPERATIVE COGNITIVE DYSFUNCTION WATERSTONE PHARMACEUTICALS WUHAN CO LTD (CN) 2024-05-08 — — EP disclosed
EP-4346905-A1 EGFR TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES Merck Patent GmbH (DE) 2024-04-10 — — EP disclosed
US-11939314-B2 Quinolin-2-one derivatives MERCK PATENT GMBH (DE) 2024-03-26 — — US disclosed
EP-4333900-A2 HER2 TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES Merck Patent GmbH (DE) 2024-03-13 — — EP disclosed
WO-2024042007-A1 SUBSTITUTED BICYCLES AS HSET INHIBITORS MERCK PATENT GMBH (DE) 2024-02-29 — — WO disclosed
EP-3687989-B1 SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUND AND USE THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2024-02-28 — — EP disclosed
EP-3802501-B1 COMPOUNDS AS NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XWPHARMA LTD (KY) 2024-02-28 — — EP disclosed
US-11905247-B2 Compounds as neurokinin-1 receptor antagonists and uses thereof XWPharma Ltd. (KY) 2024-02-20 — — US disclosed
US-20040072822-A1 N,N-disubstituted diazocycloalkanes RECORDATI S.A. (CH) 2004-04-15 — — US disclosed
US-20040072839-A1 1-Phenylalkylpiperazines RECORDATI S.A. (CH) 2004-04-15 — — US disclosed
US-20040058962-A1 Phenylalkylamines and pyridylalkylamines RECORDATI S.A. (CH) 2004-03-25 — — US disclosed
WO-2003106444-A1 N,N-DISUBSTITUTED DIAZOCYCLOALKANES USEFUL FOR THE TREATMENT OF CNS DISORDERS DUE TO SEROTONERGIC DYSFUNCTION RECORDATI S.A. (CH) 2003-12-24 — — WO disclosed
WO-2003106443-A1 1-PHENYLALKYL-PIPERAZINES RECORDATI S.A. (CH) 2003-12-24 — — WO disclosed
WO-2003106421-A2 PHENYLALKYLAMINES AND PYRIDYLALKYLAMINES RECORDATI S.A. (CH) 2003-12-24 — — WO disclosed
US-20030181446-A1 Novel N-acylated heterocycles RECORDATI S.A. 2003-09-25 — — US disclosed
US-20030162777-A1 Novel N-acylated heterocycles RECORDATI S.A. 2003-08-28 — — US disclosed
WO-2003031436-A1 HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF DISORDERS OF THE URINARY TRACT RECORDATI S.A. (CH) 2003-04-17 — — WO disclosed
EP-0944590-B1 AMINOGUANIDINES AND ALKOXYGUANIDINES AS PROTEASE INHIBITORS DIMENSIONAL PHARM INC (US) 2002-03-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072822-A1 N,N-disubstituted diazocycloalkanes HTR1D, HTR1A, HTR2C THRB 1476/4885HTR1A 2/4885CA12 4669/4885
US-20040058962-A1 Phenylalkylamines and pyridylalkylamines HTR1A, HTR5A, HTR3A THRB 1307/4885HTR1A 1/4885CA12 4885/4885
US-20040072839-A1 1-Phenylalkylpiperazines HTR5A, HTR1A, HTR1D THRB 1463/4885HTR1A 2/4885CA12 4883/4885
US-20030162777-A1 Novel N-acylated heterocycles HTR1A, HTR1D, HTR1E THRB 882/4885HTR1A 1/4885CA12 4758/4885
US-11905247-B2 Compounds as neurokinin-1 receptor antagonists and uses thereof TACR1, KISS1R, TACR2 THRB 1309/4885HTR1A 137/4885CA12 1820/4885
US-11939314-B2 Quinolin-2-one derivatives KIT, CDK2, CDK1 THRB 3452/4885HTR1A 898/4885CA12 3364/4885
US-20030181446-A1 Novel N-acylated heterocycles HTR1A, HTR1E, HTR2C THRB 1289/4885HTR1A 1/4885CA12 4869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.